Showing results (101-110 of 396) with videos related to
Sort By:
Pageof 40
Annals of Hematology|December 22, 1999
Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cellsJ Braess, J Pförtner, W Kern, et al.Leukemia Research|January 1, 1990
Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trialW Hiddemann, M Zühlsdorf, B Wörmann, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1987
Cytostatic effects in osteosarcomas as detected by flow cytometric DNA analysis after preoperative chemotherapy according to the COSS 80/82 protocolT Bösing, A Roessner, W Hiddemann, et al.Blut|August 1, 1990
Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimenW Stenzinger, A Blömker, W Hiddemann, et al.British Journal of Haematology|August 6, 2000
Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterationsL Maeck, D Haase, C Schoch, et al.British Journal of Haematology|December 21, 2000
Differential cellular expression of the human MSH2 protein in normal and myelodysplastic haematopoiesisL Maeck, P Kohaus, D Haase, et al.Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS|November 1, 1995
[Pharmacokinetics of buprenorphine in subcutaneous administration]I Gralow, W F von Hornstein, E Schleyer, et al.Hematological Oncology|July 1, 1989
Treatment of refractory acute myeloid leukemia with mAMSA and VP 16-213 in combination: results of a clinical phase I/II studyW Hiddemann, D Urbanitz, P Preusser, et al.Anticancer Research|March 12, 1998
Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissuesC Binder, L Binder, D Marx, et al.Schmerz (Berlin, Germany)|May 1, 1995
[Continuous subcutaneous buprenorphine application in the treatment of cancer pain.]I Gralow, W F von Hornstein, E Schleyer, et al.Pageof 40